Pharmaceutical Website Links Receiving FDA Scrutiny, Ad Division Says
Executive Summary
FDA's advertising division is examining the content of sites to which pharmaceutical product websites provide links.
You may also be interested in...
FDA Internet Enforcement Without Guidance May Create "Incongruity" - Lilly
FDA's decision to halt work on an Internet guidance could result in enforcement "incongruity," Lilly Associate Internet Consultant Michael Pozsgai told a Drug Information Association conference in Washington D.C. Nov. 3.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials